Lack of persistent remission following initial recovery in patients with type 1 diabetes treated with autologous peripheral blood stem cell transplantation

• Published in: Diabetes research and clinical practice Vol. 143; pp. 357 - 363
• Main Authors: Walicka, Magdalena, Milczarczyk, Alicja, Snarski, Emilian, Jedynasty, Krystyna, Halaburda, Kazimierz, Torosian, Tigran, Urbanowska, Elżbieta, Król, Małgorzata, Jędrzejczak, Wiesław Wiktor, Franek, Edward
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier B.V 01-09-2018
• Subjects: Autologous peripheral blood stem cell transplantation; Glucose; Glycated hemoglobin; Metabolic control; Type 1 diabetes mellitus; Autologous peripheral blood stem cell transplantation; Glycated hemoglobin; Glucose; Metabolic control; Type 1 diabetes mellitus; autologous peripheral blood stem cell transplantation; type 1 diabetes mellitus; glucose; metabolic control; glycated hemoglobin
• ISSN: 0168-8227; 1872-8227
• DOI: 10.1016/j.diabres.2018.07.020

To assess metabolic control in patients with newly diagnosed type 1 diabetes mellitus who underwent immunoablation followed by autologous peripheral blood stem cell transplantation (APBSCT) as a treatment of diabetes.
APBSCT was performed in 23 patients. Control group comprised 8 non-APBSCT patients in whom after diagnosis insulin therapy was initiated. Fasting plasma glucose, glycated hemoglobin, fasting and postprandial C-peptide were assessed in all subjects and continuous glucose monitoring was performed at 6th, 12th, 24th, 36th, 48th month after transplantation. The APBSCT group was observed for 72 months.
Six months after the procedure, 22 of 23 transplant patients remained insulin-free, but after 6 years, there was only one APBSCT insulin-free patient. Good glycemic control was observed in all patients throughout the observation period, although fasting plasma glucose in control group was significantly higher in comparison with the both transplanted groups up to the 36th month. HbA1c values were significantly lower in the insulin-free group only at the 24th and 36th month. Fasting and postprandial C-peptide concentrations were higher in APBSCT group as compared with control group. The most serious adverse event was a fatal case of Pseudomonas aeruginosa sepsis.
The effectiveness of APBSCT as a treatment for newly diagnosed DM1 seems to be limited in time. The metabolic control of APBSCT patients is similar to conventionally treated patients. The lower fasting plasma glucose and higher C-peptide achieved with APBSCT seem to not exceed the risks associated with the procedure.